Want to see GUTS full AI Analyst Report?
GUTS Stock Chart & Stats
$0.77
$0.02(2.15%)
At close: 4:00 PM EDT
$0.77
$0.02(2.15%)
Day’s Range― - ―
52-Week Range$0.38 - $2.45
Previous Close$1.96
Volume1.77M
Average Volume (3M)1.90M
Market Cap
$108.67M
Enterprise Value$70.21
Total Cash (Recent Filing)$63.17M
Total Debt (Recent Filing)$60.82M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 10, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding158,648,960
10 Day Avg. Volume2,922,976
30 Day Avg. Volume1,897,530
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)17.64
Price to Sales (P/S)0.00
P/FCF Ratio-1.84
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.80Price Target Upside523.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Pivotal ExecutionA fully randomized pivotal (>300 patients, >30 U.S. sites) with >90% retention and predefined co-primary endpoints materially de-risks regulatory and commercial paths. Durable benefit: strong trial execution increases likelihood of credible evidence for approval, payer engagement, and hospital adoption over the next 2–6 months and beyond.
Regulatory & Reimbursement MomentumPositive regulatory signals and active reimbursement planning (de novo feedback, Breakthrough designation, CMS RAPID, CPT work) reduce structural commercialization friction. Over the medium term this supports faster Medicare access and hospital reimbursement, improving adoption economics and long-term revenue prospects if approvals materialize.
Pipeline Diversification — Rejuva AdvancesAdvancing RJVA-001 to first-in-human status makes the company a dual clinical-stage biotech, diversifying beyond Revita. A successful Rejuva program could create a one-time gene-therapy revenue stream and long-term upside, materially changing the company's risk/return profile relative to a single-procedure asset.
Bears Say
Pre-revenue & High BurnPre-revenue status with TTM net loss (~$108M) and operating/FCF burn (~-$87.7M) is a durable constraint: sustained negative cash generation forces reliance on external funding or partnerships, limits strategic flexibility, and increases dilution risk absent clear near-term commercialization or licensing revenue.
Limited Cash RunwayA runway into early 2027 with a closed ATM and no planned pre-pivotal raise creates a structural financing vulnerability. Any timing slips or additional spending needs will force near-term capital raises or partnerships under potentially unfavorable terms, compressing long-term shareholder value and execution optionality.
Binary Catalyst & Regulatory RiskReliance on a sequence of pivotal and midpoint readouts and on regulatory pathways like de novo/RAPID is a persistent execution risk. Binary outcomes or regulatory delays can rapidly alter approval, coverage, and funding prospects, making long-term operational and financing plans highly contingent on a small set of events.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.38 and its highest was $2.44 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $108.67M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 3 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on May 12, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.22.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 158,648,960 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 29.155%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fractyl Health, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.80 (523.38% Upside)
$4.80 (523.38% Upside)
Blogger Sentiment
Bullish
GUTS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $108.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.68%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
GUTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical execution, external validation, regulatory and reimbursement progress, and a clear catalyst timeline — all supportive of the company's strategic thesis. Financially, the company has reduced operating spend and improved adjusted EBITDA, but remains cash-limited with a runway into early 2027 and continues to report negative adjusted profitability. Several regulatory and operational uncertainties remain (RAPID implementation, full de novo approval, U.S. regulatory engagement for Rejuva) and the near-term plan is contingent on multiple upcoming clinical readouts. Overall, clinical and regulatory momentum and cost discipline are material positives, but the constrained cash runway and remaining execution/regulatory risks temper the outlook.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$4.80
▲(523.38% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
6.64% Insiders
4.29% Mutual Funds
0.22% Other Institutional Investors
85.09% Public Companies and Individual Investors